Symbols / LEXX
LEXX Chart
About
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. The company's DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, epilepsy, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, and oral products; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 15.68M |
| Enterprise Value | 10.97M | Income | -10.79M | Sales | 522.00K |
| Book/sh | 0.22 | Cash/sh | 0.18 | Dividend Yield | — |
| Payout | 0.00% | Employees | 7 | IPO | — |
| P/E | — | Forward P/E | -1.62 | PEG | — |
| P/S | 30.04 | P/B | 2.85 | P/C | — |
| EV/EBITDA | -1.05 | EV/Sales | 21.01 | Quick Ratio | 3.10 |
| Current Ratio | 3.68 | Debt/Eq | 2.25 | LT Debt/Eq | — |
| EPS (ttm) | -0.57 | EPS next Y | -0.39 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-01-13 15:00 | ROA | -82.96% |
| ROE | -155.23% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -20.15% | Profit Margin | 0.00% | Shs Outstand | 24.89M |
| Shs Float | 23.54M | Short Float | 2.63% | Short Ratio | 2.40 |
| Short Interest | — | 52W High | 1.90 | 52W Low | 0.46 |
| Beta | 0.52 | Avg Volume | 624.76K | Volume | 252.60K |
| Target Price | $4.50 | Recom | Strong_buy | Prev Close | $0.63 |
| Price | $0.63 | Change | -0.28% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$4.50
Mean price target
2. Current target
$0.63
Latest analyst target
3. DCF / Fair value
$-3.46
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.63
Low
$1.50
High
$6.00
Mean
$4.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-26 | main | HC Wainwright & Co. | Buy → Buy | $2 |
| 2025-07-29 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-07-01 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-01-24 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-12-02 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-11-25 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-07-18 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-07-10 | init | HC Wainwright & Co. | — → Buy | $10 |
| 2024-03-05 | main | Maxim Group | Buy → Buy | $12 |
| 2023-07-21 | init | Maxim Group | — → Buy | $2 |
- Lexaria (NASDAQ: LEXX) prices $3.5M direct stock offering, adds 5-year warrants - Stock Titan Mon, 15 Dec 2025 08
- Lexaria Bioscience stock plunges after $3.5M at-the-market offering - Investing.com Mon, 15 Dec 2025 08
- $LEXX stock is down 29% today. Here's what we see in our data. - Quiver Quantitative Fri, 26 Sep 2025 07
- Mixed Catalysts Drive After-Hours Moves In MRM, LEXX, SHOT, AQST, And OVID - Nasdaq hu, 25 Sep 2025 07
- Lexaria Bioscience (LEXX) Stock Drops After Terminating Sales Ag - GuruFocus Fri, 26 Sep 2025 07
- Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Investing News Network Mon, 29 Sep 2025 07
- Experimental liraglutide pill shows similar results, 67% less nausea - Stock Titan hu, 05 Feb 2026 08
- We Think Lexaria Bioscience (NASDAQ:LEXX) Needs To Drive Business Growth Carefully - Yahoo Finance Sat, 05 Apr 2025 07
- Is It Too Late to Buy Lexaria Stock? - StocksToTrade Fri, 26 Sep 2025 07
- Lexaria Releases Annual Letter from the CEO - ACCESS Newswire Mon, 12 Jan 2026 08
- Here's Why We're Watching Lexaria Bioscience's (NASDAQ:LEXX) Cash Burn Situation - simplywall.st Fri, 21 Mar 2025 07
- Lexaria Bioscience raises $3.5 million in at-market offering - Investing.com Mon, 15 Dec 2025 08
- Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Investing News Network Fri, 26 Sep 2025 07
- Lexaria Bioscience closes $3.5 million registered direct offering - Investing.com ue, 16 Dec 2025 08
- Experimental oral GLP-1 pill cuts side effects by nearly half in trial - Stock Titan ue, 23 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 27500 | 25241 | — | Purchase at price 0.91 - 0.92 per share. | BUNKA CHRISTOPHER ANDREW | Director | — | 2025-07-30 00:00:00 | I |
| 1 | 15000 | 13641 | — | Purchase at price 0.91 per share. | CHRISTOPHER RICHARD C | Chief Executive Officer | — | 2025-07-29 00:00:00 | D |
| 2 | 5376 | 4989 | — | Purchase at price 0.93 per share. | DOCHERTY JOHN MARTIN | President | — | 2025-07-29 00:00:00 | D |
| 3 | 5000 | 4532 | — | Purchase at price 0.91 per share. | MCKECHNIE WILLIAM EDWARD | Director | — | 2025-07-29 00:00:00 | D |
| 4 | 750 | 682 | — | Purchase at price 0.91 per share. | CARLE VANESSA | Officer | — | 2025-07-29 00:00:00 | D |
| 5 | 100000 | — | — | Stock Award(Grant) at price 0.00 per share. | BUNKA CHRISTOPHER ANDREW | Director | — | 2025-01-07 00:00:00 | D |
| 6 | 50000 | 118392 | — | Purchase at price 2.24 - 2.47 per share. | CHRISTOPHER RICHARD C | Chief Executive Officer | — | 2024-12-03 00:00:00 | D |
| 7 | 1600 | 5008 | — | Purchase at price 3.13 per share. | TURKEL CATHERINE C | Director | — | 2024-08-12 00:00:00 | D |
| 8 | 2567 | 10268 | — | Sale at price 4.00 per share. | CARLE VANESSA | Officer | — | 2024-07-31 00:00:00 | D |
| 9 | 2500 | 2875 | — | Conversion of Exercise of derivative security at price 1.15 per share. | CARLE VANESSA | Officer | — | 2024-05-14 00:00:00 | D |
Financials
| Line Item | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -11.76M | -5.61M | -6.17M | -5.75M |
| TotalUnusualItems | -33.71K | -69.83K | -221.69K | -764.61K |
| TotalUnusualItemsExcludingGoodwill | -33.71K | -69.83K | -221.69K | -764.61K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -11.90M | -5.80M | -6.66M | -7.27M |
| ReconciledDepreciation | 87.83K | 76.15K | 145.40K | 102.72K |
| ReconciledCostOfRevenue | 2.72K | 4.82K | 31.50K | 71.84K |
| EBITDA | -11.79M | -5.68M | -6.39M | -6.52M |
| EBIT | -11.88M | -5.75M | -6.53M | -6.62M |
| NetInterestIncome | 3.02K | 14.31K | 43.19K | 0.00 |
| InterestIncome | 3.02K | 14.31K | 43.19K | 0.00 |
| NormalizedIncome | -11.87M | -5.73M | -6.44M | -6.50M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -11.90M | -5.80M | -6.66M | -7.27M |
| TotalExpenses | 12.59M | 6.22M | 6.76M | 6.87M |
| TotalOperatingIncomeAsReported | -11.88M | -5.75M | -6.53M | -6.62M |
| DilutedAverageShares | 18.00M | 12.38M | 6.61M | 5.89M |
| BasicAverageShares | 18.00M | 12.38M | 6.61M | 5.89M |
| DilutedEPS | -0.66 | -0.47 | -1.01 | -1.24 |
| BasicEPS | -0.66 | -0.47 | -1.01 | -1.24 |
| DilutedNIAvailtoComStockholders | -11.90M | -5.80M | -6.66M | -7.27M |
| NetIncomeCommonStockholders | -11.90M | -5.80M | -6.66M | -7.27M |
| NetIncome | -11.90M | -5.80M | -6.66M | -7.27M |
| MinorityInterests | 9.59K | 13.31K | 47.63K | 114.33K |
| NetIncomeIncludingNoncontrollingInterests | -11.91M | -5.81M | -6.71M | -7.38M |
| NetIncomeDiscontinuousOperations | 0.00 | -22.00K | ||
| NetIncomeContinuousOperations | -11.91M | -5.81M | -6.71M | -7.38M |
| PretaxIncome | -11.91M | -5.81M | -6.71M | -7.38M |
| OtherIncomeExpense | -33.71K | -69.83K | -221.69K | -764.61K |
| SpecialIncomeCharges | 0.00 | 1.52M | ||
| GainOnSaleOfPPE | 0.00 | 1.52M | ||
| GainOnSaleOfSecurity | -33.71K | -69.83K | -221.69K | -764.61K |
| NetNonOperatingInterestIncomeExpense | 3.02K | 14.31K | 43.19K | 0.00 |
| InterestIncomeNonOperating | 3.02K | 14.31K | 43.19K | 0.00 |
| OperatingIncome | -11.88M | -5.75M | -6.53M | -6.62M |
| OperatingExpense | 12.58M | 6.21M | 6.73M | 6.80M |
| ResearchAndDevelopment | 8.24M | 2.36M | 3.67M | 1.84M |
| SellingGeneralAndAdministration | 4.35M | 3.85M | 3.06M | 4.96M |
| GeneralAndAdministrativeExpense | 4.35M | 3.85M | 3.06M | 4.96M |
| OtherGandA | 4.35M | 3.85M | 3.06M | 4.96M |
| GrossProfit | 703.20K | 459.46K | 194.71K | 183.56K |
| CostOfRevenue | 2.72K | 4.82K | 31.50K | 71.84K |
| TotalRevenue | 705.92K | 464.28K | 226.21K | 255.40K |
| OperatingRevenue | 705.92K | 463.38K | 190.97K | 168.00K |
| Line Item | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 19.56M | 15.81M | 8.09M | 5.95M |
| ShareIssued | 19.56M | 15.81M | 8.09M | 5.95M |
| TotalDebt | 109.32K | 137.37K | 163.97K | 49.99K |
| TangibleBookValue | 2.68M | 7.52M | 2.58M | 7.46M |
| InvestedCapital | 2.99M | 8.04M | 3.04M | 7.95M |
| WorkingCapital | 1.97M | 6.80M | 1.88M | 6.78M |
| NetTangibleAssets | 2.68M | 7.52M | 2.58M | 7.46M |
| CapitalLeaseObligations | 109.32K | 137.37K | 163.97K | 49.99K |
| CommonStockEquity | 2.99M | 8.04M | 3.04M | 7.95M |
| TotalCapitalization | 2.99M | 8.04M | 3.04M | 7.95M |
| TotalEquityGrossMinorityInterest | 2.60M | 7.66M | 2.68M | 7.63M |
| MinorityInterest | -386.94K | -377.35K | -364.04K | -316.41K |
| StockholdersEquity | 2.99M | 8.04M | 3.04M | 7.95M |
| GainsLossesNotAffectingRetainedEarnings | -70.33K | -19.82K | 0.00 | |
| OtherEquityAdjustments | -70.33K | -19.82K | ||
| RetainedEarnings | -63.46M | -51.56M | -45.76M | -39.10M |
| AdditionalPaidInCapital | 66.50M | 59.60M | 48.80M | 47.04M |
| CapitalStock | 19.56K | 15.81K | 8.09K | 5.95K |
| CommonStock | 19.56K | 15.81K | 8.09K | 5.95K |
| TotalLiabilitiesNetMinorityInterest | 1.57M | 1.21M | 403.91K | 201.44K |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 78.90K | 109.32K | 136.17K | 7.40K |
| LongTermDebtAndCapitalLeaseObligation | 78.90K | 109.32K | 136.17K | 7.40K |
| LongTermCapitalLeaseObligation | 78.90K | 109.32K | 136.17K | 7.40K |
| CurrentLiabilities | 1.49M | 1.10M | 267.74K | 194.04K |
| CurrentDeferredLiabilities | 0.00 | 4.96K | 0.00 | |
| CurrentDeferredRevenue | 0.00 | 4.96K | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 30.42K | 28.05K | 27.79K | 42.59K |
| CurrentCapitalLeaseObligation | 30.42K | 28.05K | 27.79K | 42.59K |
| CurrentDebt | 7.93K | |||
| OtherCurrentBorrowings | 7.93K | |||
| PayablesAndAccruedExpenses | 1.46M | 1.07M | 239.94K | 151.45K |
| Payables | 1.46M | 1.07M | 239.94K | 151.45K |
| OtherPayable | 76.50K | 63.00K | 45.00K | |
| DuetoRelatedPartiesCurrent | 5.22K | |||
| TotalTaxPayable | 21.51K | 8.53K | 14.90K | 31.30K |
| IncomeTaxPayable | 1.05K | |||
| AccountsPayable | 1.37M | 1.06M | 225.04K | 120.15K |
| TotalAssets | 4.18M | 8.87M | 3.08M | 7.83M |
| TotalNonCurrentAssets | 706.78K | 969.80K | 932.77K | 856.41K |
| NonCurrentAccountsReceivable | 64.01K | 63.58K | 48.56K | |
| GoodwillAndOtherIntangibleAssets | 307.82K | 516.68K | 462.62K | 488.46K |
| OtherIntangibleAssets | 307.82K | 516.68K | 462.62K | 488.46K |
| NetPPE | 334.94K | 389.55K | 421.59K | 367.95K |
| AccumulatedDepreciation | -568.84K | -517.62K | -475.17K | -379.99K |
| GrossPPE | 903.79K | 907.17K | 896.76K | 747.94K |
| Leases | 259.98K | 259.98K | 259.98K | 259.98K |
| OtherProperties | 541.90K | 545.28K | 534.87K | 386.05K |
| MachineryFurnitureEquipment | 101.91K | 101.91K | 101.91K | 101.91K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 3.47M | 7.90M | 2.15M | 6.98M |
| PrepaidAssets | 1.13M | 1.19M | 546.78K | 576.76K |
| Inventory | 0.00 | 38.42K | 29.65K | |
| RawMaterials | 0.00 | 38.42K | 29.65K | |
| Receivables | 368.36K | 154.48K | 126.69K | 201.78K |
| OtherReceivables | 174.00K | 84.00K | 24.64K | 37.25K |
| TaxesReceivable | 194.36K | 70.48K | 102.05K | 84.16K |
| AccountsReceivable | 48.56K | 80.37K | 16.55K | |
| CashCashEquivalentsAndShortTermInvestments | 1.97M | 6.56M | 1.48M | 6.16M |
| OtherShortTermInvestments | 165.36K | 55.81K | 125.64K | 347.33K |
| CashAndCashEquivalents | 1.80M | 6.50M | 1.35M | 5.81M |
| CashFinancial | 1.80M | 6.50M | 1.35M | 5.81M |
| Line Item | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|
| FreeCashFlow | -10.55M | -5.15M | -6.05M | -5.06M |
| RepaymentOfDebt | 0.00 | -44.60K | -66.69K | |
| IssuanceOfCapitalStock | 6.05M | 4.21M | 1.59M | 0.00 |
| CapitalExpenditure | -99.75K | -188.60K | -169.61K | -180.64K |
| IncomeTaxPaidSupplementalData | 10.04K | 8.21K | 4.78K | 16.30K |
| EndCashPosition | 1.80M | 6.50M | 1.35M | 5.81M |
| BeginningCashPosition | 6.50M | 1.35M | 5.81M | 10.92M |
| EffectOfExchangeRateChanges | -50.52K | -19.82K | 0.00 | |
| ChangesInCash | -4.65M | 5.17M | -4.46M | -5.10M |
| FinancingCashFlow | 6.05M | 10.32M | 1.59M | -44.60K |
| CashFlowFromContinuingFinancingActivities | 6.05M | 10.32M | 1.59M | -44.60K |
| ProceedsFromStockOptionExercised | 0.00 | 6.11M | 0.00 | 0.00 |
| NetCommonStockIssuance | 6.05M | 4.21M | 1.59M | 0.00 |
| CommonStockIssuance | 6.05M | 4.21M | 1.59M | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | -44.60K | -66.69K | |
| NetLongTermDebtIssuance | 0.00 | -44.60K | -66.69K | |
| LongTermDebtPayments | 0.00 | -44.60K | -66.69K | |
| InvestingCashFlow | -243.02K | -188.60K | -169.61K | -180.64K |
| CashFlowFromContinuingInvestingActivities | -243.02K | -188.60K | -169.61K | -180.64K |
| NetOtherInvestingChanges | -49.19K | 273.37K | ||
| NetInvestmentPurchaseAndSale | -143.27K | 0.00 | 0.00 | |
| SaleOfInvestment | 0.00 | |||
| NetIntangiblesPurchaseAndSale | -75.11K | -145.59K | -135.86K | -131.45K |
| PurchaseOfIntangibles | -75.11K | -145.59K | -131.45K | -79.49K |
| NetPPEPurchaseAndSale | -24.65K | -43.01K | -33.75K | -49.19K |
| PurchaseOfPPE | -24.65K | -43.01K | -33.75K | -49.19K |
| OperatingCashFlow | -10.45M | -4.96M | -5.88M | -4.88M |
| CashFlowFromContinuingOperatingActivities | -10.45M | -4.96M | -5.88M | -4.88M |
| ChangeInWorkingCapital | 195.58K | 106.56K | 143.26K | -351.48K |
| ChangeInOtherWorkingCapital | -4.96K | 4.96K | -44.26K | |
| ChangeInOtherCurrentLiabilities | -37.09K | -33.27K | -44.81K | 0.00 |
| ChangeInPayablesAndAccruedExpense | 396.64K | 826.47K | 88.49K | 45.50K |
| ChangeInPayable | 826.47K | 88.49K | 45.50K | -39.68K |
| ChangeInAccountPayable | 826.47K | 88.49K | 50.73K | 13.80K |
| ChangeInPrepaidAssets | 55.31K | -641.03K | 29.98K | -257.51K |
| ChangeInInventory | 0.00 | 43.07K | -1.98K | 95.04K |
| ChangeInReceivables | -214.32K | -50.57K | 26.54K | -137.49K |
| ChangesInAccountReceivables | -213.88K | -35.55K | 26.54K | -137.49K |
| OtherNonCashItems | 37.07K | 39.27K | 43.79K | 1.24M |
| StockBasedCompensation | 859.49K | 492.24K | 170.38K | 752.59K |
| UnrealizedGainLossOnInvestmentSecurities | 33.71K | 69.83K | 221.69K | 764.61K |
| AssetImpairmentCharge | 247.36K | 65.60K | 106.76K | 0.00 |
| DepreciationAmortizationDepletion | 87.83K | 76.15K | 145.40K | 102.72K |
| DepreciationAndAmortization | 87.83K | 76.15K | 145.40K | 102.72K |
| Depreciation | 141.31K | 147.60K | ||
| OperatingGainsLosses | -7.93K | -736.81K | ||
| GainLossOnInvestmentSecurities | 785.89K | |||
| NetIncomeFromContinuingOperations | -11.91M | -5.81M | -6.71M | -7.38M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for LEXX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|